M&A Deal Summary

AstraZeneca Acquires Icosavax

On December 12, 2023, AstraZeneca acquired life science company Icosavax for 1.1B USD

Acquisition Highlights
  • This is AstraZeneca’s 14th transaction in the Life Science sector.
  • This is AstraZeneca’s 10th largest (disclosed) transaction.
  • This is AstraZeneca’s 10th transaction in the United States.
  • This is AstraZeneca’s 1st transaction in Washington.

M&A Deal Summary
Date 2023-12-12
Target Icosavax
Sector Life Science
Buyer(s) AstraZeneca
Deal Type Add-on Acquisition
Deal Value 1.1B USD

Target

Icosavax

Seattle, Washington, United States
Icosavax is a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Icosavax was founded in 2017 and is based in Seattle, Washington.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

AstraZeneca

Cambridge, United Kingdom
Category Company
Founded 1992
Sector Life Science
Employees83,100
Revenue 45.8B USD (2023)
DESCRIPTION
Main office on AstraZeneca's campus in Waltham, Massachusetts.
Main office on AstraZeneca's campus in Waltham, Massachusetts.

AstraZeneca is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in several major disease areas, including oncology, cardiovascular, renal & metabolism, and respiratory & immunology. The Company's aim is to improve the health and quality of life of patients around the world through medicines, treatment solutions, and accessibility to healthcare. AstraZeneca is involved in both the research and development (R&D) and manufacturing of drugs to address critical areas of unmet medical need. AstraZeneca was founded in 1992 and is based in Cambridge, United Kingdom.

DEAL STATS #
Overall 16 of 19
Sector (Life Science) 14 of 17
Type (Add-on Acquisition) 12 of 15
State (Washington) 1 of 1
Country (United States) 10 of 10
Year (2023) 1 of 2
Size (of disclosed) 10 of 17
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-11-29 Neogene Therapeutics

Santa Monica, California, United States

Neogene Therapeutics is a global biotechnology company focused on discovering, developing and manufacturing next-generation, transformative TCR therapies targeting neoantigens in solid cancers. Neogene Therapeutics is based in Santa Monica, California.

Buy $320M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2023-12-26 Gracell Biotechnologies

Suzhou, China

Gracell Biotechnologies is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. Gracell Biotechnologies was founded in 2017 and is based in Suzhou, China.

Buy $1.2B
Mergr

Product

Company

Legal